Ubenimex administered by daily oral gavage significantly decreased polyp formation in C57BL/6J-ApcMin/+ mice compared with untreated controls. In 615 mice bearing MFC-LAP3-overexpressing tumors, Ubenimex alone at 5 mg/kg reduced tumor volume by 37.5% compared with the DMSO + PBS control. [2,3]
Ubenimex reduces polyp formation in mice
Animal study · C57BL/6J-ApcMin/+ mice; n = 6 [2]
C57BL/6J-ApcMin/+ mice received Ubenimex at 5 or 15 mg/kg by daily oral gavage for 8 weeks. Polyp formation decreased significantly compared with the untreated control group.
Conditions shared by the study groups
- Route
- oral gavage
- Treatment course
- daily for 8 weeks
- Ubenimex 5 or 15 mg/kg
- Model: C57BL/6J-ApcMin/+ mice; n = 6
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Ubenimex; Compound label in the paper: Bestatin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Patients and methods > Mouse model and drug administration (S35, S38); Results > Bestatin reduces intestinal adenoma formation in ApcMin/+ mice (S119, S121); Fig. 6 legend (S186, S187, S188)
Polyp number: Polyp number; comparator: untreated control group — Patients and methods > Mouse model and drug administration (S38); Fig. 6 legend (S186, S187)
Ubenimex 5 or 15 mg/kg · Patients and methods > Mouse model and drug administration (S38); Results > Bestatin reduces intestinal adenoma formation in ApcMin/+ mice (S121); Fig. 6 legend (S187)
Ubenimex reduces tumor volume in mice bearing MFC tumors
Animal study · 615 mice bearing MFC-LAP3-overexpressing tumors; n = 3 per group [3]
Ubenimex (5 mg/kg) was given daily via oral gavage. Ubenimex alone reduced tumor volume by 37.5%. Tumor growth inhibition ratio, calculated as (V0−Ve)/V[0], where V[0] = baseline volume and Ve = endpoint volume.
Conditions shared by the study groups
- Route
- oral gavage
- Treatment course
- daily; 16-day treatment
- Ubenimex 5 mg/kg
- Model: 615 mice bearing MFC-LAP3-overexpressing tumors; n = 3 per group
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Ubenimex
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Methods > Mouse models (S84); Results > Ubenimex sensitizes anti PD-L1 blockade in syngeneic mouse GC models (S103, S104, S105, S106, S107, S111)
tumor volume: tumor volume; comparator: DMSO + PBS (control); Tumor growth inhibition ratio, calculated as (V0−Ve)/V[0], where V[0] = baseline volume and Ve = endpoint volume — Results > Ubenimex sensitizes anti PD-L1 blockade in syngeneic mouse GC models (S105, S107, S111)
Ubenimex 5 mg/kg · Methods > Mouse models (S84); Results > Ubenimex sensitizes anti PD-L1 blockade in syngeneic mouse GC models (S105, S107, S111)